Intrinsic value of bluebird bio - BLUE

Previous Close

$116.49

  Intrinsic Value

$7.95

stock screener

  Rating & Target

str. sell

-93%

Previous close

$116.49

 
Intrinsic value

$7.95

 
Up/down potential

-93%

 
Rating

str. sell

We calculate the intrinsic value of BLUE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  36
  37
  38
  39
  40
  41
  43
  44
  46
  48
  50
  52
  54
  56
  59
  61
  64
  67
  70
  73
  76
  80
  84
  88
  92
  96
  101
  106
  111
  116
Variable operating expenses, $m
  317
  324
  332
  342
  352
  363
  375
  389
  403
  418
  432
  449
  468
  488
  509
  531
  555
  580
  606
  634
  663
  694
  727
  761
  798
  836
  876
  918
  963
  1,009
Fixed operating expenses, $m
  226
  231
  236
  241
  246
  252
  257
  263
  269
  275
  281
  287
  293
  300
  306
  313
  320
  327
  334
  342
  349
  357
  365
  373
  381
  389
  398
  406
  415
  425
Total operating expenses, $m
  543
  555
  568
  583
  598
  615
  632
  652
  672
  693
  713
  736
  761
  788
  815
  844
  875
  907
  940
  976
  1,012
  1,051
  1,092
  1,134
  1,179
  1,225
  1,274
  1,324
  1,378
  1,434
Operating income, $m
  -507
  -518
  -530
  -544
  -558
  -574
  -590
  -607
  -626
  -645
  -663
  -685
  -707
  -731
  -757
  -783
  -811
  -840
  -870
  -902
  -936
  -971
  -1,008
  -1,046
  -1,087
  -1,129
  -1,173
  -1,219
  -1,267
  -1,318
EBITDA, $m
  -491
  -502
  -514
  -527
  -541
  -556
  -572
  -588
  -606
  -625
  -645
  -666
  -688
  -711
  -736
  -761
  -788
  -816
  -845
  -876
  -909
  -942
  -978
  -1,015
  -1,054
  -1,094
  -1,137
  -1,181
  -1,228
  -1,276
Interest expense (income), $m
  0
  8
  9
  9
  9
  10
  10
  11
  12
  12
  13
  14
  14
  15
  16
  17
  18
  19
  20
  22
  23
  24
  26
  27
  29
  31
  32
  34
  36
  38
  40
Earnings before tax, $m
  -515
  -527
  -539
  -553
  -568
  -584
  -601
  -619
  -638
  -658
  -677
  -699
  -723
  -748
  -774
  -801
  -830
  -860
  -892
  -925
  -960
  -997
  -1,035
  -1,075
  -1,117
  -1,161
  -1,207
  -1,255
  -1,305
  -1,358
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -515
  -527
  -539
  -553
  -568
  -584
  -601
  -619
  -638
  -658
  -677
  -699
  -723
  -748
  -774
  -801
  -830
  -860
  -892
  -925
  -960
  -997
  -1,035
  -1,075
  -1,117
  -1,161
  -1,207
  -1,255
  -1,305
  -1,358

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  723
  739
  758
  780
  803
  829
  857
  888
  921
  956
  994
  1,034
  1,077
  1,123
  1,172
  1,223
  1,277
  1,335
  1,395
  1,460
  1,527
  1,599
  1,674
  1,753
  1,836
  1,924
  2,017
  2,114
  2,217
  2,324
Adjusted assets (=assets-cash), $m
  723
  739
  758
  780
  803
  829
  857
  888
  921
  956
  994
  1,034
  1,077
  1,123
  1,172
  1,223
  1,277
  1,335
  1,395
  1,460
  1,527
  1,599
  1,674
  1,753
  1,836
  1,924
  2,017
  2,114
  2,217
  2,324
Revenue / Adjusted assets
  0.050
  0.050
  0.050
  0.050
  0.050
  0.049
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
  0.050
Average production assets, $m
  201
  205
  210
  216
  223
  230
  238
  246
  256
  265
  276
  287
  299
  312
  325
  339
  354
  370
  387
  405
  424
  444
  464
  486
  510
  534
  560
  587
  615
  645
Working capital, $m
  -65
  -67
  -68
  -70
  -72
  -75
  -77
  -80
  -83
  -86
  -89
  -93
  -97
  -101
  -105
  -110
  -115
  -120
  -126
  -131
  -137
  -144
  -151
  -158
  -165
  -173
  -181
  -190
  -199
  -209
Total debt, $m
  162
  168
  176
  184
  193
  204
  215
  227
  240
  253
  268
  284
  301
  319
  338
  358
  380
  402
  426
  451
  478
  506
  535
  567
  599
  634
  670
  708
  749
  791
Total liabilities, $m
  284
  291
  298
  306
  316
  326
  337
  349
  362
  376
  391
  407
  423
  441
  460
  481
  502
  525
  548
  574
  600
  628
  658
  689
  722
  756
  793
  831
  871
  913
Total equity, $m
  439
  449
  460
  473
  488
  503
  520
  539
  559
  580
  603
  628
  654
  682
  711
  742
  775
  810
  847
  886
  927
  970
  1,016
  1,064
  1,115
  1,168
  1,224
  1,283
  1,345
  1,411
Total liabilities and equity, $m
  723
  740
  758
  779
  804
  829
  857
  888
  921
  956
  994
  1,035
  1,077
  1,123
  1,171
  1,223
  1,277
  1,335
  1,395
  1,460
  1,527
  1,598
  1,674
  1,753
  1,837
  1,924
  2,017
  2,114
  2,216
  2,324
Debt-to-equity ratio
  0.370
  0.370
  0.380
  0.390
  0.400
  0.400
  0.410
  0.420
  0.430
  0.440
  0.440
  0.450
  0.460
  0.470
  0.480
  0.480
  0.490
  0.500
  0.500
  0.510
  0.520
  0.520
  0.530
  0.530
  0.540
  0.540
  0.550
  0.550
  0.560
  0.560
Adjusted equity ratio
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -515
  -527
  -539
  -553
  -568
  -584
  -601
  -619
  -638
  -658
  -677
  -699
  -723
  -748
  -774
  -801
  -830
  -860
  -892
  -925
  -960
  -997
  -1,035
  -1,075
  -1,117
  -1,161
  -1,207
  -1,255
  -1,305
  -1,358
Depreciation, amort., depletion, $m
  16
  16
  17
  17
  17
  18
  18
  19
  19
  20
  18
  19
  19
  20
  21
  22
  23
  24
  25
  26
  27
  29
  30
  31
  33
  34
  36
  38
  40
  42
Funds from operations, $m
  -499
  -510
  -523
  -536
  -551
  -566
  -583
  -600
  -619
  -638
  -659
  -680
  -703
  -727
  -753
  -779
  -807
  -837
  -867
  -899
  -933
  -968
  -1,005
  -1,044
  -1,084
  -1,127
  -1,171
  -1,217
  -1,266
  -1,317
Change in working capital, $m
  -1
  -1
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
Cash from operations, $m
  -498
  -509
  -521
  -534
  -549
  -564
  -580
  -597
  -616
  -635
  -655
  -677
  -700
  -723
  -748
  -775
  -802
  -831
  -862
  -894
  -927
  -962
  -998
  -1,037
  -1,077
  -1,119
  -1,163
  -1,209
  -1,257
  -1,307
Maintenance CAPEX, $m
  -13
  -13
  -13
  -14
  -14
  -14
  -15
  -15
  -16
  -16
  -17
  -18
  -19
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -29
  -30
  -31
  -33
  -34
  -36
  -38
  -40
New CAPEX, $m
  -6
  -5
  -5
  -6
  -7
  -7
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -26
  -27
  -28
  -30
Cash from investing activities, $m
  -19
  -18
  -18
  -20
  -21
  -21
  -23
  -23
  -25
  -26
  -27
  -29
  -31
  -32
  -33
  -35
  -37
  -39
  -41
  -43
  -45
  -47
  -50
  -52
  -54
  -57
  -60
  -63
  -66
  -70
Free cash flow, $m
  -517
  -527
  -540
  -554
  -569
  -585
  -603
  -621
  -641
  -661
  -683
  -706
  -730
  -755
  -782
  -810
  -839
  -870
  -902
  -936
  -972
  -1,009
  -1,048
  -1,089
  -1,131
  -1,176
  -1,223
  -1,272
  -1,323
  -1,376
Issuance/(repayment) of debt, $m
  7
  7
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  23
  24
  25
  27
  28
  30
  31
  33
  35
  36
  38
  40
  42
Issuance/(repurchase) of shares, $m
  525
  537
  551
  566
  582
  600
  618
  637
  658
  680
  699
  723
  749
  775
  803
  832
  863
  895
  929
  964
  1,001
  1,040
  1,081
  1,123
  1,168
  1,214
  1,263
  1,314
  1,368
  1,424
Cash from financing (excl. dividends), $m  
  532
  544
  558
  574
  591
  610
  629
  649
  671
  694
  714
  739
  766
  793
  822
  852
  884
  918
  953
  989
  1,028
  1,068
  1,111
  1,154
  1,201
  1,249
  1,299
  1,352
  1,408
  1,466
Total cash flow (excl. dividends), $m
  16
  17
  19
  21
  23
  25
  26
  28
  30
  32
  31
  34
  36
  38
  40
  43
  45
  48
  50
  53
  56
  59
  62
  66
  69
  73
  77
  81
  85
  89
Retained Cash Flow (-), $m
  -525
  -537
  -551
  -566
  -582
  -600
  -618
  -637
  -658
  -680
  -699
  -723
  -749
  -775
  -803
  -832
  -863
  -895
  -929
  -964
  -1,001
  -1,040
  -1,081
  -1,123
  -1,168
  -1,214
  -1,263
  -1,314
  -1,368
  -1,424
Prev. year cash balance distribution, $m
  1,194
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  685
  -520
  -532
  -545
  -560
  -575
  -592
  -609
  -628
  -647
  -668
  -690
  -713
  -737
  -763
  -790
  -818
  -848
  -879
  -911
  -945
  -981
  -1,018
  -1,057
  -1,098
  -1,141
  -1,186
  -1,233
  -1,283
  -1,334
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  657
  -476
  -463
  -449
  -434
  -417
  -400
  -381
  -361
  -339
  -317
  -294
  -271
  -248
  -224
  -201
  -178
  -156
  -135
  -116
  -98
  -81
  -67
  -54
  -43
  -33
  -25
  -19
  -14
  -10
Current shareholders' claim on cash, %
  74.6
  55.7
  41.5
  30.9
  23.0
  17.2
  12.8
  9.5
  7.1
  5.3
  4.0
  3.0
  2.2
  1.7
  1.3
  1.0
  0.7
  0.5
  0.4
  0.3
  0.2
  0.2
  0.1
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

FINANCIAL RATIOS  of  bluebird bio (BLUE)

Valuation Ratios
P/E Ratio -18
Price to Sales 790
Price to Book 5.5
Price to Tangible Book
Price to Cash Flow -24.9
Price to Free Cash Flow -21.7
Growth Rates
Sales Growth Rate -57.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 300%
Cap. Spend. - 3 Yr. Gr. Rate 25.5%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 13.8%
Total Debt to Equity 13.8%
Interest Coverage 0
Management Effectiveness
Return On Assets -24.9%
Ret/ On Assets - 3 Yr. Avg. -19.6%
Return On Total Capital -27.8%
Ret/ On T. Cap. - 3 Yr. Avg. -22.3%
Return On Equity -30.7%
Return On Equity - 3 Yr. Avg. -23.6%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -4233.3%
EBITDA Margin - 3 Yr. Avg. -1868.1%
Operating Margin -4466.7%
Oper. Margin - 3 Yr. Avg. -1972.6%
Pre-Tax Margin -4400%
Pre-Tax Margin - 3 Yr. Avg. -1945.6%
Net Profit Margin -4400%
Net Profit Margin - 3 Yr. Avg. -1929.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 6.6%
Payout Ratio 0%

BLUE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BLUE stock intrinsic value calculation we used $35.427 million for the last fiscal year's total revenue generated by bluebird bio. The default revenue input number comes from 0001 income statement of bluebird bio. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BLUE stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BLUE is calculated based on our internal credit rating of bluebird bio, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of bluebird bio.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BLUE stock the variable cost ratio is equal to 877.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $221 million in the base year in the intrinsic value calculation for BLUE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for bluebird bio.

Corporate tax rate of 27% is the nominal tax rate for bluebird bio. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BLUE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BLUE are equal to 555%.

Life of production assets of 15.5 years is the average useful life of capital assets used in bluebird bio operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BLUE is equal to -179.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1623.432 million for bluebird bio - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.119 million for bluebird bio is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of bluebird bio at the current share price and the inputted number of shares is $5.8 billion.

RELATED COMPANIES Price Int.Val. Rating
CELG Celgene 69.63 340.31  str.buy
SGMO Sangamo Therap 9.51 3.03  str.sell
EDIT Editas Medicin 26.90 1.10  str.sell
NTLA Intellia Thera 17.01 2.46  str.sell
BLCM Bellicum Pharm 4.37 1.25  str.sell
XLRN Acceleron Phar 50.00 2.00  str.sell

COMPANY NEWS

▶ Waiting for bluebird bio to Sing at ASH   [Nov-09-18 04:32PM  Motley Fool]
▶ Here's Why bluebird bio Fell 21.4% in October   [Nov-07-18 10:32PM  Motley Fool]
▶ 3 Cancer Stocks to Watch in December   [09:16AM  Motley Fool]
▶ 3 Top Biotech Stocks to Buy in November   [08:24AM  Motley Fool]
▶ Bluebird: 3Q Earnings Snapshot   [05:14PM  Associated Press]
▶ Here's Why I'm Not Selling My Celgene Shares   [Oct-26-18 08:34AM  Motley Fool]
▶ Here's Why bluebird bio Dropped 13.3% in September   [Oct-11-18 01:41PM  Motley Fool]
▶ Bluebird Bio Stock May Have Upside of at Least 60 Percent   [Sep-12-18 06:00PM  InvestorPlace]
▶ Software and Biotech Are Eating the World   [Aug-30-18 06:06PM  Zacks]
▶ Play The Future of Gene Therapy With These 5 Biotech Stocks   [Aug-27-18 12:14PM  InvestorPlace]
▶ East Bay biotech's different approach to cancer leads to $80 million IPO   [Aug-23-18 05:47PM  American City Business Journals]
▶ Lake Union biotech leases signal resurgence of life science market   [03:48PM  American City Business Journals]
▶ Carl Icahn Fires Shots at Express Scripts   [Aug-09-18 10:25PM  Motley Fool]
▶ Why this company's Durham outpost may benefit from $100M investment   [Aug-07-18 11:30AM  American City Business Journals]
▶ Can These Biotech Companies Catch Novartis, Gilead In CAR-T?   [Aug-06-18 04:15PM  Investor's Business Daily]
▶ Stocks Slip As Intel Downgrade Crimps Dow, Qualcomm Upgraded   [09:40AM  Investor's Business Daily]
▶ Bluebird: 2Q Earnings Snapshot   [09:45AM  Associated Press]
▶ Could Celgene Shake Up the CAR-T Market?   [04:16PM  Motley Fool]
▶ #ASCO18: A Weekend of Surprises   [Jun-03-18 02:10PM  Motley Fool]
▶ Is bluebird bio Incs (NASDAQ:BLUE) Liquidity Good Enough?   [May-17-18 12:27PM  Simply Wall St.]
▶ bluebird bio Looks for Data Ahead   [May-09-18 04:55PM  Motley Fool]
▶ bluebird bio to Present at Investor Conferences in May   [May-08-18 08:00AM  Business Wire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.